News
Can "Ultra-low" dose Rituximab work for RA?
The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.
RA: Cardiovascular Risk Stratification and Potential Predictors of Risk
Early cardiovascular disease assessment and management is critical at diagnosis in patients with Rheumatoid Arthritis (RA).
Day 4 Report from ACR21
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
Cognitive Impairment in Patients with Rheumatoid Arthritis
Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive impairment.
ACR21 Best Abstracts - Day 4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Predictors of Remission and Low Disease Activity in SLE
A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus. The goal of treatment in SLE is aimed at remission or low disease activit
ACR21 – Day 3 Report
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Monitoring Infliximab Drug Levels Improves Efficacy
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Risks associated with mortality in VEXAS
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition.
Telemedicine Enriched Care Model for Autoinflammatory Diseases
Traditionally telemedicine is thought to be a technology where a patient directly talks to a provider or a specialist; however, another concept of having a patient with a local primary care who in turn accesses specialists via video conferencing, is gaining some momentum.
